Remdesivir: Quo vadis

Remdesivir (GS-5734, Veklury (R)) has remained the only antiviral drug formally approved by the US FDA for the treatment of Covid-19 (SARS-CoV-2 infection). Its key structural features are the fact that it is a C-nucleoside (adenosine) analogue, contains a 1'-cyano function, and could be considered as a ProTide based on the presence of a phosphoramidate group. Its antiviral spectrum and activity in animal models have been well established and so has been its molecular mode of action as a delayed chain terminator of the viral RdRp (RNA-dependent RNA polymerase). Its clinical efficacy has been evaluated, but needs to be optimized with regard to timing, dosage and duration of treatment, and route of administration. Safety, toxicity and pharmacokinetics need to be further addressed, and so are its potential combinations with other drugs such as corticosteroids (i.e. dexamethasone) and ribavirin.

Automated summary

Remdesivir is the only antiviral drug formally approved by the US FDA for the treatment of Covid-19. Its key structural features and mode of action have been well established, but further optimization in clinical application is needed in terms of dosage, timing, route of administration, and potential combinations with other drugs for efficacy evaluation.